[Polaprezinc]

Nihon Rinsho. 2002 Feb:60 Suppl 2:717-20.
[Article in Japanese]
No abstract available

Publication types

  • Review

MeSH terms

  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Amoxicillin / therapeutic use
  • Animals
  • Anti-Ulcer Agents* / pharmacology
  • Anti-Ulcer Agents* / therapeutic use
  • Carnosine* / analogs & derivatives*
  • Carnosine* / pharmacology
  • Carnosine* / therapeutic use
  • Clarithromycin / therapeutic use
  • Clinical Trials as Topic
  • Drug Resistance, Bacterial
  • Drug Synergism
  • Drug Therapy, Combination
  • Helicobacter Infections / complications
  • Helicobacter Infections / drug therapy*
  • Helicobacter pylori / drug effects
  • Helicobacter pylori / enzymology
  • Humans
  • Lansoprazole
  • Metronidazole / therapeutic use
  • Omeprazole / analogs & derivatives*
  • Omeprazole / therapeutic use
  • Organometallic Compounds* / pharmacology
  • Organometallic Compounds* / therapeutic use
  • Peptic Ulcer / drug therapy
  • Peptic Ulcer / etiology
  • Urease / antagonists & inhibitors
  • Zinc Compounds

Substances

  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Anti-Ulcer Agents
  • Organometallic Compounds
  • Zinc Compounds
  • Lansoprazole
  • polaprezinc
  • Metronidazole
  • Amoxicillin
  • Carnosine
  • Urease
  • Clarithromycin
  • Omeprazole